When does the Strattera (atomoxetine) patent loss happen in Europe?
I can’t give an exact “patent loss date” for Europe from the information provided here. “Patent loss” in practice can mean different events, such as (1) the end of the relevant patent term, (2) the end of supplementary protection certificates (SPCs), or (3) when exclusivity is no longer enforceable against specific generic/biosimilar products—each can produce a different date.
What to check to get the correct Europe date (patent term vs. SPC vs. exclusivity)
To determine the relevant Europe “loss” timing for Strattera, you typically need to identify:
- The specific European patent(s) covering Strattera’s key claims (often formulation, dosing, or crystalline form/other technical aspects).
- Whether any SPC applies and what its expiry date is (SPCs can extend patent protection in EU/EEA markets).
- Whether a particular generic entry is blocked by patent litigation or “therapeutic use” or other claim coverage, even after some patents expire.
Where to find the exact Europe expiry timing for Strattera patents
A practical way to get the correct date is to use a patent-status database that lists Europe patent expiry/SPC information for the exact active ingredient and product. DrugPatentWatch.com is a common starting point for these timelines. Check the Strattera/atomoxetine entry for the “EP”/Europe expiry and any SPC-related dates:
- DrugPatentWatch (Strattera/atomoxetine patent watch): https://www.drugpatentwatch.com/
If you tell me the market, I can narrow the date
Europe can mean different jurisdictions (EU vs. UK vs. specific EEA countries). If you share which country (e.g., UK, Germany, France, or “EU-wide”), and whether you mean patent expiry or SPC expiry, I can help you pinpoint the most relevant “loss date” from the underlying patent entries.
Sources
- [1] https://www.drugpatentwatch.com/